• Home
  • CYP19A1
  • Mouse Anti-CYP19A1 Recombinant Antibody (1513)

Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901)

See all CYP19A1 antibodies
Go to compare Compare Online Inquiry
Published Data
V2LY-0125-LY901-1
Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901) in IF
Immunofluorescence (IF) staining characterizations of mesoderm marker (GATA4) and GC markers (AMHR2, CYP19A1) in differentiation condition #2. The luteinized cumulus granulosa cells served as IF positive control cells. Scale bar, 50μm. ...View More
Chen, W. J., Chao, Y. Y., Huang, W. K., Chang, W. F., Tzeng, C. R., Chuang, C. H., ... & Lu, J. (2024). Identification of apelin/APJ signaling dysregulation in a human iPSC-derived granulosa cell model of Turner syndrome. Cell Death Discovery, 10(1), 468. Distributed under Open Access license CC BY 4.0, without modification.
V2LY-0125-LY901-2
Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901) in IF
Confocal images of immunofluorescence staining showed expression of steroidogenic markers STAR and CYP19A1 in non-induced (-DOX -TMP) and induced (+DOX +TMP) conditions at day 10 of gonadal differentiation. Images were taken with a ×40 objective. Scale bars 50 µm. ...View More
Danti, L., Lundin, K., Sepponen, K., Yohannes, D. A., Kere, J., Tuuri, T., & Tapanainen, J. S. (2023). CRISPR/Cas9-mediated activation of NR5A1 steers female human embryonic stem cell-derived bipotential gonadal-like cells towards a steroidogenic cell fate. Journal of ovarian research, 16(1), 194. Distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
V2LY-0125-LY901-3
Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901) in IHC
Representative images of immunohistochemistry (IHC) staining of CYP19A1 and PD-L1 protein in human colon cancer tissue microarrays. ...View More
Liu, L., Mo, M., Chen, X., Chao, D., Zhang, Y., Chen, X., ... & Yang, J. (2023). Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. Journal of Experimental & Clinical Cancer Research, 42(1), 85. Distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
V2LY-0125-LY901-4
Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901) in IF
The correlations between CYP19A1 expression and PD-L1 level in CAFs and macrophages were analyzed by immunofluorescence. Scale bars, 50 μm. ...View More
Liu, L., Mo, M., Chen, X., Chao, D., Zhang, Y., Chen, X., ... & Yang, J. (2023). Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. Journal of Experimental & Clinical Cancer Research, 42(1), 85. Distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
V2LY-0125-LY901-5
Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901) in WB
The level of CYP19A1 protein expression was measured in HT29 and HCT116 cells transfected with CYP19A1 siRNA (si-CYP19A1) or si-Scram. Human PBMCs were cocultured with the letrozole (5 μM) or si-CYP19A1-treated HT29 cells or HCT116 cells for 24 h. ...View More
Liu, L., Mo, M., Chen, X., Chao, D., Zhang, Y., Chen, X., ... & Yang, J. (2023). Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. Journal of Experimental & Clinical Cancer Research, 42(1), 85. Distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
V2LY-0125-LY901-6
Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901) in FC
The percentage of IFN-γ+ or CD107a+ CD8+ cells were determined by flow cytometry. ...View More
Liu, L., Mo, M., Chen, X., Chao, D., Zhang, Y., Chen, X., ... & Yang, J. (2023). Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. Journal of Experimental & Clinical Cancer Research, 42(1), 85. Distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
V2LY-0125-LY901-7
Mouse Anti-CYP19A1 Recombinant Antibody (1513) (V2LY-0125-LY901) in IHC
The black triangles indicate the follicle formation, and the red arrows indicate the significant CYP19 accumulation (the brown area). At different stages of follicle maturation, CYP19 accumulation was higher in the THSG-fed group than in the untreated control group. As the mice aged, CYP19 accumulation remained at higher levels in the THSG-treated group compared to the untreated control group. ...View More
Lin, H. Y., Yang, Y. N., Chen, Y. F., Huang, T. Y., Crawford, D. R., Chuang, H. Y., ... & Wang, K. (2022). 2, 3, 5, 4'-Tetrahydroxystilbene-2-O-β-D-Glucoside improves female ovarian aging. Frontiers in Cell and Developmental Biology, 10, 862045. Distributed under Open Access license CC BY 4.0, without modification.
Datasheet
SDS
Request for COA
Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal
Mouse
Clone
1513
Application
WB, IP, IF, ELISA, IHC-P
Immunogen
Amino acids 204-503 mapping at the C-terminus of human CYP19.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal Antibody
Application Notes
ApplicationNote
WB1:100-1:1,000
IP1-2 μg per 100-500 μg of total protein (1 mL of cell lysate)
IF(ICC)1:50-1:500
ELISA1:100-1:1,000
IHC-P1:50-1:500

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
Gelatin & PBS
Preservative
Sodium Azide
Concentration
0.2 mg/mL
Purity
>95% as determined by analysis by SDS-PAGE
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.
More Infomation

Target

Full Name
Cytochrome P450 Family 19 Subfamily A Member 1
Entrez Gene ID
1588
UniProt ID
P11511
Function
A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively (PubMed:27702664, PubMed:2848247).

Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta hydrogen abstraction combined with cleavage of the C10-C19 bond to yield a phenolic A ring and formic acid (PubMed:20385561).

Alternatively, the third oxidative reaction yields a 19-norsteroid and formic acid. Converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and may play a role in homeostasis of this potent androgen (PubMed:22773874).

Also displays 2-hydroxylase activity toward estrone (PubMed:22773874).

Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:20385561, PubMed:22773874).
Biological Process
Androgen catabolic process Source: CAFA
Estrogen biosynthetic process Source: Reactome
Female gonad development Source: GO_Central
Positive regulation of estradiol secretion Source: CAFA
Response to estradiol Source: GO_Central
Steroid biosynthetic process Source: ProtInc
Sterol metabolic process Source: Reactome
Cellular Location
Endoplasmic reticulum membrane; Microsome membrane
Involvement in disease
Aromatase excess syndrome (AEXS):
An autosomal dominant disorder characterized by increased extraglandular aromatization of steroids that presents with heterosexual precocity in males and isosexual precocity in females.
Aromatase deficiency (AROD):
A rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency. Thus, pregnant women exhibit a hirsutism, which spontaneously resolves after post-partum. At birth, female babies present with pseudohermaphroditism due to virilization of extern genital organs. In adult females, manifestations include delay of puberty, breast hypoplasia and primary amenorrhoea with multicystic ovaries.
PTM
Phosphorylated in vitro by PKA and PKG/PRKG1. These phosphorylations inhibit the catalytic activity as measured by estrone synthesis from androstenedione (36% decrease for PKA and 30% for PKG/PRKG1).

Parween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J. P., ... & Pandey, A. V. (2020). Molecular basis of CYP19A1 deficiency in a 46, XX patient with R550W mutation in POR: Expanding the PORD phenotype. The Journal of Clinical Endocrinology & Metabolism, 105(4), e1272-e1290.

Hosseini, E., Shahhoseini, M., Afsharian, P., Karimian, L., Ashrafi, M., Mehraein, F., & Afatoonian, R. (2019). Role of epigenetic modifications in the aberrant CYP19A1 gene expression in polycystic ovary syndrome. Archives of medical science: AMS, 15(4), 887.

Khayeka-Wandabwa, C., Ma, X., Cao, X., Nunna, V., Pathak, J. L., Bernhardt, R., ... & Bureik, M. (2019). Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans. International immunopharmacology, 73, 64-71.

Kaur, R., Kaur, T., & Kaur, A. (2018). Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. Journal of assisted reproduction and genetics, 35(6), 1123-1129.

Kaewlert, W., Sakonsinsiri, C., Namwat, N., Sawanyawisuth, K., Ungarreevittaya, P., Khuntikeo, N., ... & Thanan, R. (2018). The importance of CYP19A1 in estrogen receptor-positive cholangiocarcinoma. Hormones and Cancer, 9(6), 408-419.

Castro-Piedras, I., Sharma, M., den Bakker, M., Molehin, D., Martinez, E. G., Vartak, D., ... & Pruitt, K. (2018). DVL1 and DVL3 differentially localize to CYP19A1 promoters and regulate aromatase mRNA in breast cancer cells. Oncotarget, 9(86), 35639.

El-Bayomi, K. M., Saleh, A. A., Awad, A., El-Tarabany, M. S., El-Qaliouby, H. S., Afifi, M., ... & El-Magd, M. A. (2018). Association of CYP19A1 gene polymorphisms with anoestrus in water buffaloes. Reproduction, Fertility and Development, 30(3), 487-497.

Magnani, L., Frige, G., Gadaleta, R. M., Corleone, G., Fabris, S., Kempe, H., ... & Minucci, S. (2017). Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nature genetics, 49(3), 444-450.

Flück, C. E., & Pandey, A. V. (2017). Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase. The Journal of steroid biochemistry and molecular biology, 165, 64-70.

Wang, J., & Gong, Y. (2017). Transcription of CYP19A1 is directly regulated by SF-1 in the theca cells of ovary follicles in chicken. General and Comparative Endocrinology, 247, 1-7.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CYP19A1 Recombinant Antibody (1513)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Rabbit Anti-CYP19A1 Recombinant Antibody (
1H1) (CAT#: V2LY-0725-LY685)

Rabbit Anti-CYP19A1 Recombinant Antibody (1512) (CAT#: V2LY-0125-LY900)

Mouse Anti-CYP19A1 Recombinant Antibody (CBCNC-549) (CAT#: V2LY-0125-LY904)

Rabbit Anti-CYP19A1 Recombinant Antibody (CBNH-042) (CAT#: V2LY-0125-LY905)

Rat Cyp19a1 ELISA Kit (CAT#: V2LY-0626-LY1258)

Rat Cyp19a1 ELISA Kit (2) (CAT#: V2LY-0626-LY2982)

Mouse Cyp19a1 ELISA Kit (CAT#: V2LY-0626-LY2051)

Mouse Anti-CYP19A1 Recombinant Antibody (2B6) (CAT#: V2LY-0125-LY902)

Human CYP19A1 ELISA Kit (CAT#: V2LY-0626-LY3772)

Mouse Anti-CYP19A1 Recombinant Antibody (CBFYC-2563) (CAT#: V2LY-0125-LY903)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry
Request bulk or custom quote Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

online inquiry
Online Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.